Tandem Diabetes Care Inc. (TNDM)
TNDM Q4 Earnings & Revenues Beat Estimates, Gross Margin & Stock Up
Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript
Tandem Diabetes Care (TNDM) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.44 per share a year ago.
Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Tandem Diabetes Care (TNDM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.
Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. ( TNDM ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - Executive VP, CFO & Treasurer Conference Call Participants Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Danielle Antalffy - UBS Investment Bank, Research Division Michael Kratky - Leerink Partners LLC, Research Division Joanne Wuensch - Citigroup Inc. Exchange Research Suraj Kalia - Oppenheimer & Co. Inc., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Polark - Wolfe Research, LLC Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Stephanie Piazzola - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Tandem Diabetes Care: An Earnings Miss Confirms The Bear Case - Downgrade To Sell
Downgrading Tandem Diabetes Care to sell after Q2 2025 earnings confirms core U.S. business weakness and deteriorating profitability. Intense competition from Insulet and Medtronic is eroding Tandem's market share, with rivals showing stronger growth and profitability. Management's credibility is under pressure, due to material guidance downgrades and reactive strategy, despite upcoming product catalysts.
